Fast Facts: Biosimilars in Hematology and Oncology : Biologics and Biosimilars - Getting Decisions Right
Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days'exposure in Europe, shows that approved biosimilars can b...
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
S. Karger
2020
|
| Subjects: | |
| Online Access: | View this record in EBSCOhost |
| Summary: | Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days'exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options.'Fast Facts: Biosimilars in Hematology and Oncology'provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. |
|---|